Natalie Gillson
Neurology with Special Qualifications in Child Neurology · Fort Myers, FLNPI 1821397456
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $201,240 of the $249,877 with a category attached, or 80.5%. Biogen accounts for 92.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $60,070 and has fallen 83.9% since, to $9,666 in 2025. Among neurology with special qualifications in child neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 413 payments — averaging $605.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$231K
- Neurelis, Inc.$16K
- Livanova USA, Inc.$1K
- UCB, Inc.$462
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$191
- Genentech USA, Inc.$136
- plus $922 from 23 others
What the payments were for
- Consulting fees$5,4762%
- Speaking & faculty fees$201,24081%
- Travel & lodging$36,10514%
- Food & beverage$7,0563%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 328 | $230,595 |
| Neurelis, Inc. | 17 | $16,085 |
| Livanova USA, Inc. | 8 | $1,486 |
| UCB, Inc. | 17 | $462 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 2 | $191 |
| Genentech USA, Inc. | 2 | $136 |
| Eisai Inc. | 2 | $106 |
| SK Life Science, Inc. | 1 | $90 |
| Otter Pharmaceuticals, LLC | 3 | $86 |
| Sunovion Pharmaceuticals Inc. | 5 | $79 |
| Corium, LLC | 3 | $71 |
| Aucta Pharmaceuticals, Inc. | 3 | $66 |
| Tris Pharma Inc | 4 | $66 |
| Jazz Pharmaceuticals Inc. | 2 | $50 |
| Catalyst Pharmaceuticals, Inc. | 1 | $34 |
| Novartis | 2 | $33 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Nobelpharma America, LLC | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Sarepta Therapeutics, Inc. | 1 | $23 |
| Greenwich Biosciences, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Zogenix Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Saol Therapeutics Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Aquestive Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPINRAZA$225,298
- VALTOCO$15,967
- VNS Therapy$1,362
- EVRYSDI$123
- ZOLGENSMA$103
How this compares
$249,877 in reported general payments places this provider in the 95th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Fort Myers
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ronald DavisWinter Park$154K
- Ian MillerMiami$104K
- Michael HammerSaint Petersburg$100K
- Matt LallasMiami$88K
- Jose FerreiraTampa$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.